| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eea8577cff34693b361c6039650f7dbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee31b1a75e89a211c6f446ffcffd13d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eec920e3b72c8aa3a5f3a2a3ff1becd5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3155069b833b184bcd4ad12f7100dd4c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 |
| filingDate |
2012-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a76e375a1a315888273f29c1ce83bfc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80f0c844afda0086533297a4a9759da6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66c9604f4d2513142fbbbb56fb6ae8e0 |
| publicationDate |
2013-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013289121-A1 |
| titleOfInvention |
Pulmonary disease treatment and diagnosis based on arhgef1 |
| abstract |
Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10913798-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016172726-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019157337-A1 |
| priorityDate |
2011-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |